Bander Balkhi

Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating autoimmune diseases in Jordan

Autoimmune diseases are increasingly prevalent, and their management in Jordan relies heavily on costly intravenous infliximab (IV IFX). Subcutaneous infliximab (IFX SC) may offer cost savings by reducing administration-related expenses. This study aims to investigate the financi...